HTB homepage • Conference reports • Articles by subject • Subscribe October 2016 Contents Editorial September/October 2016: Volume 17 Number 9/10 Conference reports 18th International Workshop on Comorbidities, 12-13 September, New York, USA Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring Bone loss with PrEP in MSM aged 18-24 Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study 21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa Four day a week ART: sub-optimal drug levels but few virological failures Large disparities in costs of antiretrovirals between low- and middle-income countries High risk of virological failure and loss to follow up postpartum in South Africa Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women High death rates among HIV positive women postpartum accessing ARVs Higher rates of eye complications in HIV positive people on ART Short reports on selected Durban posters Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban Raltegravir-based third-line ART in children and adolescents 8th International Workshop on HIV Paediatrics, 15-16 July 2016. Durban, South Africa Raltegravir in HIV-exposed neonates Virological response without routine viral load monitoring in children: results from the ARROW trial Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s Antiretrovirals First generic TDF/FTC approved in EU Single-pill PI-based combination submitted to EMA Dolutegravir superior to standard dose efavirenz in WHO analysis Treatment access First generic version of dolutegravir approved by the FDA Brazil to start using dolutegravir first-line in its national programme Global Fund to reach US $13 billion target for 2017-2019: UK pledges up to $1.3 billion Guidelines US DHHS guidelines updated (July 2016) HIV prevention and transmission PrEP update: EU approval, extended access for PROUD participants, TAF studies underway Cure-related research HIV persistence: defective virus copies accumulate rapidly after infection On the web Conference materials and online publications PDFs September/October 2016: Volume 17 Number 9/10 HTB homepage • Conference reports • Articles by subject • Subscribe
